Which antiplatelet is preferred for long-term secondary prevention?
For how long do we prescribe dual antiplatelet therapy in CAD patients?
When to add oral anticoagulant for long-term secondary prevention?
Is there any role for aspirin in primary prevention?
Should we prescribe PPI to any patient receiving antiplatelet therapy?
Let's discuss the evidence beyond the answers of these questions.
2021 ESC Guidelines of CVD Prevention
www.escardio.o...
2020 ESC Guidelines of Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation.
www.escardio.o...
2019 Guidelines of Management of Chronic Coronary Syndromes
www.escardio.o...
2017 Guidelines of Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation
www.escardio.o...
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
www.nejm.org/d...
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
www.nejm.org/d...
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE)
www.thelancet....
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
www.nejm.org/d...
Colchicine Cardiovascular Outcomes Trial - COLCOT
www.acc.org/la...
Colchicine in Patients with Chronic Coronary Disease
www.nejm.org/d...
7 сен 2024